PUBLISHER: Grand View Research | PRODUCT CODE: 1986426
PUBLISHER: Grand View Research | PRODUCT CODE: 1986426
The global leadless pacemakers market size was estimated at USD 982.42 million in 2025 and is projected to reach USD 1,622.87 million by 2033, growing at a CAGR of 6.56% from 2026 to 2033. The increasing prevalence of cardiac disorders and associated risk factors is expected to drive demand for advanced device-based therapies.
According to an Oxford Academic article published in January 2025, globally, the age-standardized prevalence of cardiovascular disease is estimated at approximately 7,179 cases per 100,000 people, emphasizing the significant and growing burden of cardiac conditions. This high prevalence has amplified the need for innovative pacing solutions to manage rhythm disorders more safely and effectively. Leadless pacemakers have emerged as a transformative advancement in this field, offering a minimally invasive alternative to traditional pacemakers by eliminating the need for leads and surgical pockets. Leadless pacemakers (PMs) have become a well-established therapeutic option over the past decade, offering significant advantages over traditional transvenous pacemakers. According to the NCBI article published in April 2025, eliminating leads and subcutaneous pockets, leadless devices such as Micra and Aveir substantially reduce the risk of infections and long-term complications such as electrode dislocation, pocket hematomas, pneumothorax, endocarditis, and venous obstruction. Data from the Micra PAR registry, which followed 1,809 patients for a mean of 51 months, reported a five-year major complication rate of only 4.5%, with most occurring within 30 days of implantation. Notably, no infections required device removal, and system revisions were rare, primarily for device upgrades or battery depletion.
Technological advances have further expanded the use of leadless pacemakers. VDD(R) pacing in Micra AV and DDD(R) pacing in Aveir DR enable synchronized atrioventricular pacing, allowing treatment of a broader patient population, including those with high infection risk, limited vascular access, or prior device infections. Long-term data also demonstrate stable electrical performance and battery longevity, with over 95% of devices remaining functional at five years. Compared with historical transvenous cohorts, leadless PMs show a 53% reduction in major complications and system revisions, making them a safer and increasingly preferred choice for patients requiring long-term pacing therapy.
Global Leadless Pacemakers Market Report Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global leadless pacemakers market report based on chambers, brands, end use, and region: